Hypertrophic cardiomyopathy (HCM) is a primary cardiac disease characterised by a diverse clinical expression'-6 in which premature sudden unexpected death has been regarded as a critical feature of its natural history.'-23 However, it is also apparent that not all patients within the disease spectrum are at equal risk of premature death, and indeed in some individuals the disease seems to convey little or no risk.'7-'9 24 25 Consequently, intense investigative interest and substantial energy have been directed toward the identification of "risk factors"-that is, those features of the disease that are perceived to predispose specific patients with HCM to sudden death or cardiac arrest.7 8 12 14 16-19 26-31 Nevertheless, despite these exploratory studies in risk stratification, there are few comprehensive and prospectively obtained long-term data analysed in a multivariate fashion. Though knowledge is rapidly evolving and workable approaches are beginning to emerge, the definition of precise approaches for most patients and clinical situations remains incomplete. Indeed, because such controversy persists regarding the definition of risk it seems justified and timely to review the available data to summarise what is known about the risk of sudden death in HCM. We hope to show that prospective trials are needed and to evolve a practical approach and workable guidelines to aid the development of diagnostic and therapeutic strategies.
Factors influencing prevalence of sudden death Published reports indicate that premature death in patients with HCM is most often sudden and unexpected.-5 (Sudden death is defined as unexpected, non-traumatic death occurring instantaneously or within one hour after the onset of acute symptoms or signs of cardiac dysfunction.) Reported annual mortality ranges from about 1 % to 6%.2 7811 48 49 Therefore, various potential mechanisms that singly or in combination can lead to sudden death in patients with HCM have been studied in those who have experienced recurrent syncope,49 have survived cardiac arrest,50 or have been considered to be at increased risk of such events.2829 51-54 These mechanisms are undoubtedly not identical in all at risk patients and may differ in youthful and older patients. Furthermore, the origins of some mechanisms appear to be primarily haemodynamic whereas others are arrhythmic.
Proposed mechanisms of sudden death (based on such observations) include spontaneous primary ventricular tachycardia/fibrillation, paroxysmal atrial fibrillation and other supraventricular tachyarrhythmias (with or without accessory atrioventricular pathways) leading to accelerated atrioventricular conduction and ventricular fibrillation or hypotension, and conduction abnormalities involving dysfunction of the sinoatrial or atrioventricular nodes or the distal HisPurkinje system (including complete heart block).2 3 (fig 2) , with a high negative and low positive predictive accuracy (96% and 26%, respectively). The low positive predictive accuracy indicates significant heterogeneity of risk within the subset of patients with nonsustained ventricular tachycardia. It has also been suggested that non-sustained ventricular tachycardia may not have identical significance as a marker of sudden cardiac death in "stable low-risk" and unselected groups of patients with HCM compared with those into which higher risk patients have been preferentially referred.62
Despite this limitation, the finding of ventricular tachycardia on Holter monitoring remains a useful and practical non-invasive screening test for risk of sudden cardiac death in adult patients with HCM. The presence of ventricular tachycardia places the patient in a high risk group for which further risk evaluation or empirical treatment to prevent sudden death should be considered. In those patients in whom non-sustained tachycardia is a risk factor, it may primarily reflect the arrhythmogenic substrate or more specifically act as a trigger mechanism for sudden cardiac death. 2 Initially, investigators advocated treating such non-sustained runs of ventricular tachycardia with various antiarrhythmic agents. '7 18 McKenna et al reported that long-term treatment with low doses of amiodarone (maintenance dose, 150 mg/day) protected against sudden death and prolonged survival in patients with HCM ( fig 3) ; others have used antiarrhythmic agents such as quinidine and Though these relations between the extent of hypertrophy and the predisposition to sudcainamide, though there is some concern den death may be statistically significant they ut the proarrhythmic potential of these also show substantial overlap. Also, it is often nts when they are used to treat asympto-difficult to relate the magnitude of left ventrictic arrhythmias in patients with HCM. ular hypertrophy to the clinical course rrent recommendations are to perform fur-because wall thickness measurements can r risk evaluation to determine the need for change with time and with age. 68 
